Executive Summary
The 28 filings in the USA S&P 500 Healthcare intelligence stream, dated January 30, 2026, reveal predominantly neutral sentiment (19/28 neutral) with limited quantitative enriched data disclosed, showing no period-over-period trends, guidance changes, insider trades, or capital allocation details across the board. Healthcare-focused filings (Regeneron, Amgen, ProMIS Neurosciences, TuHURA Biosciences, Becton Dickinson, Avidity Biosciences) represent only ~20% but highlight key themes: neutral earnings disclosures from Regeneron and Becton Dickinson, bearish developments like Amgen's material agreement termination and TuHURA's delisting notice, and mixed signals from ProMIS's new agreement offset by equity dilution. Non-healthcare filings (mostly financials/banks like Flagstar, ChoiceOne, Tompkins) dominate with earnings reports and officer changes, suggesting cross-sector earnings season noise but no healthcare spillover trends. High materiality events (mat 8-10/10 in 7 filings) cluster around control changes, delistings, and terminations, implying elevated governance risks. Absent quantitative metrics prevents portfolio-level growth/margin synthesis, but patterns point to stable operations in big pharma/devices amid biotech turbulence. Actionable takeaway: Avoid high-risk biotechs; monitor exhibits for undisclosed metrics in neutral earnings 8-Ks.
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from January 28, 2026.
Investment Signals(12)
- Regeneron Pharmaceuticals↓(BULLISH)▲
Earnings disclosure under Item 2.02 with neutral sentiment and low risk (mat 7/10), standard filing signals operational stability absent negative flags
- Becton Dickinson↓(BULLISH)▲
Officer election/appointment + shareholder vote under Items 5.02/5.07, neutral low-risk (mat 5/10) suggests smooth governance transition
- ProMIS Neurosciences↓(BULLISH)▲
Entry into material definitive agreement (Item 1.01) offers strategic upside despite dilution, mixed sentiment mat 8/10 medium risk
- Avidity Biosciences↓(BULLISH)▲
DEFM14A filing (proxy materials) low risk mat 4/10 indicates progressing merger process without red flags
- Cibus, Inc.↓(BULLISH)▲
Item 8.01 other events neutral low risk mat 5/10, potential positive undisclosed development in biotech/ag space
- Velocity Financial↓(BULLISH)▲
Material definitive agreement (Item 1.01) + other events neutral med risk mat 7/10, could signal accretive deal
- News Corp↓(BULLISH)▲
Item 8.01 other events neutral low risk mat 4/10, informational disclosure may precede positive updates
- RCI Hospitality↓(BULLISH)▲
Item 8.01 other events neutral low risk mat 5/10, stable voluntary filing
- ARTELO Biosciences↓(BULLISH)▲
Shareholder vote results (Item 5.07) neutral low risk mat 4/10, approvals likely support continuity
- Cincinnati Financial↓(BULLISH)▲
Officer compensatory arrangements (Item 5.02) neutral med risk mat 5/10, retention-focused changes
- Esquire Financial↓(BULLISH)▲
Officer arrangements (Item 5.02) neutral med risk mat 5/10, potential talent stabilization
- USCB Financial↓(BULLISH)▲
Officer change (Item 5.02) neutral low risk mat 3/10, minor governance tweak
Risk Flags(10)
- TuHURA Biosciences/Delisting↓[HIGH RISK]▼
Notice of delisting/failure to meet listing standards (Item 3.01), bearish high risk mat 10/10 – liquidity erosion imminent
- Amgen/Termination↓[HIGH RISK]▼
Termination of material definitive agreement (Item 1.02), bearish med risk mat 8/10 – strategic setback undisclosed impacts
- Civitas Resources/Control Change↓[HIGH RISK]▼
Delisting (3.01), control change (5.01), rights mods (3.03), mixed high risk mat 10/10 – governance overhaul, liquidity loss
- ProMIS Neurosciences/Dilution↓[MEDIUM RISK]▼
Unregistered equity sales (Item 3.02) alongside new agreement, mixed med risk mat 8/10 – shareholder dilution pressure
- Kelly Services/Control Shift↓[HIGH RISK]▼
Changes in control (5.01), financial obligations (2.03), rights changes (3.03), neutral high risk mat 9/10 – unpredictable strategy pivot
- Flagstar Bank/Limited Data↓[MEDIUM RISK]▼
Dual earnings/Reg FD filings (2.02/7.01) neutral low risk but no metrics disclosed mat 3/10 – assessment opacity
- ChoiceOne Financial/Officer Change↓[MEDIUM RISK]▼
Officer change + earnings neutral low risk mat 2/10, undisclosed reasons raise turnover flags
- PEOPLES Financial/Officer Uncertainty↓[MEDIUM RISK]▼
Multiple officer change filings (5.02) neutral med risk mat 5/10 – leadership instability pattern
- Tompkins Financial/No Metrics↓[MEDIUM RISK]▼
Earnings (2.02) + events neutral low risk mat 7/10, lack of data hinders trend analysis
- MetroCity Bankshares/Limited Disclosure↓[MEDIUM RISK]▼
Earnings (2.02) neutral low risk mat 7/10, no quantitative trends visible
Opportunities(10)
- ProMIS Neurosciences/Material Agreement↓(OPPORTUNITY)◆
Strategic agreement (Item 1.01) mat 8/10 despite dilution – potential partnership alpha if biotech catalysts emerge
- Regeneron Pharmaceuticals/Earnings Stability↓(OPPORTUNITY)◆
Item 2.02 financial results neutral mat 7/10 – exhibits may reveal YoY beats in pharma sales for long position
- Avidity Biosciences/Merger Proxy↓(OPPORTUNITY)◆
DEFM14A low risk mat 4/10 – merger timeline acceleration could drive valuation rerating
- Velocity Financial/Definitive Agreement↓(OPPORTUNITY)◆
Item 1.01 new deal neutral mat 7/10 – undisclosed terms may unlock M&A premium
- Cibus, Inc./Other Events↓(OPPORTUNITY)◆
Item 8.01 biotech disclosure neutral mat 5/10 – potential pipeline or funding update for undervalued play
- Becton Dickinson/Governance Refresh↓(OPPORTUNITY)◆
Officer appointments (5.02) + votes neutral mat 5/10 – medical devices stability amid sector rotation
- ARTELO Biosciences/Shareholder Approval↓(OPPORTUNITY)◆
Item 5.07 vote results neutral mat 4/10 – financing or pipeline greenlight opportunity
- News Corp/Informational Disclosure↓(OPPORTUNITY)◆
Item 8.01 neutral mat 4/10 – cross-sector exhibits may signal healthcare adjacencies
- RCI Hospitality/Events↓(OPPORTUNITY)◆
Item 8.01 neutral mat 5/10 – operational updates for diversification
- SB Financial/Earnings↓(OPPORTUNITY)◆
Item 2.02 neutral mat 5/10 – financial sector proxy for healthcare funding environment
Sector Themes(6)
- Earnings Disclosure Cluster◆
12/28 filings (e.g., Regeneron, Flagstar, Tompkins) under Item 2.02 neutral low risk avg mat 5/10 – no disclosed YoY/QoQ trends but signals broad Q4 reporting stability, watch exhibits for healthcare revenue beats
- Officer Turnover Pattern◆
8/28 filings (e.g., Becton Dickinson, Cincinnati Financial, Esquire) Item 5.02 neutral/med risk avg mat 4/10 – frequent compensatory changes imply talent retention focus amid sector competition
- Delisting/Listing Risks◆
2/28 high-mat events (TuHURA, Civitas) bearish/mixed high risk 10/10 – rare but acute liquidity threats, biotech more vulnerable than pharma
- Agreement Volatility◆
5/28 mixed/bearish (Amgen termination, ProMIS new deal, Kelly changes) med-high risk avg mat 8/10 – M&A terminations offset by new pacts, no valuations but flags strategic flux
- Neutral Voluntary Disclosures◆
10/28 Item 7.01/8.01 neutral low risk avg mat 4/10 – Reg FD/other events lack metrics but provide non-public info release, potential pre-catalyst positioning
- Governance Overhauls◆
4/28 high risk (control changes in Civitas/Kelly) mat 9-10/10 – material rights mods/delisting combo erodes shareholder value, monitor healthcare spillovers
Watch List(8)
High risk mat 10/10 notice (Item 3.01) – track listing transfer timeline post-Jan 30, 2026 for liquidity impact
Bearish mat 8/10 Item 1.02 – monitor Q1 2026 filings/exhibits for financial/strategic fallout
Mixed dilution risk Item 3.02 mat 8/10 – watch ownership dilution and agreement details in next 8-K
High risk delisting/control shift mat 10/10 – post-Jan 30 developments on governance/new strategy
High risk mat 9/10 Items 5.01/2.03 – upcoming Reg FD clarifications on financial impacts
Neutral mat 7/10 Item 9.01 – review attached financials for undisclosed YoY trends/guidance
Neutral mat 5/10 Item 5.02 – monitor leadership impacts on med devices pipeline Feb 2026
Merger proxy low mat 4/10 – track shareholder vote outcomes and close timeline Q1 2026
Filing Analyses(28)
30-01-2026
Regeneron Pharmaceuticals, Inc. filed a Form 8-K on January 30, 2026 (AccNo: 0000872589-26-000004, Size: 735 KB), reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. This is a multi-item filing focused on financial results disclosure. No specific revenue, earnings, guidance, period-over-period comparisons, or other quantitative financial metrics are disclosed in the provided filing information.
30-01-2026
Civitas Resources, Inc. disclosed in its 8-K filing on 2026-01-30 the completion of an acquisition or disposition of assets (Item 2.01) and termination of a material definitive agreement (Item 1.02), alongside notice of delisting or failure to satisfy listing standards (Item 3.01), material modifications to rights of security holders (Item 3.03), changes in control of the registrant (Item 5.01), departures/elections of directors and officers (Item 5.02), and amendments to articles of incorporation or bylaws (Item 5.03). While the transaction completion may realize value for target stakeholders, the delisting and changes in control introduce significant negative implications including reduced liquidity and altered governance. No financial metrics, deal values, or specific parties were disclosed.
30-01-2026
Flagstar Bank, National Association filed a Form 8-K on January 30, 2026, disclosing results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet details, period-over-period comparisons, or guidance were mentioned. This is a standard earnings-related disclosure with no quantified metrics provided.
30-01-2026
Flagstar Bank, National Association filed an 8-K on January 30, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific core event, transaction details, financial metrics, or quantitative data are disclosed in the provided filing summary. This appears to be a voluntary disclosure with attached exhibits, but content details are NOT_DISCLOSED.
30-01-2026
News Corp filed an 8-K on January 30, 2026 (AccNo: 0001564708-26-000020, Size: 399 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the other event, transaction, financial impacts, or contents of the exhibits are disclosed. This appears to be a multi-item filing with informational disclosures but lacks quantitative metrics or directional implications.
30-01-2026
CHOICEONE FINANCIAL SERVICES INC filed an 8-K on January 30, 2026 (AccNo: 0001193125-26-030504, Size: 2 MB), categorized as an Officer Change event, disclosing under Item 2.02 Results of Operations and Financial Condition and Item 9.01 Financial Statements and Exhibits. No specific details on the officer position affected, appointment or resignation, reasons for change, financial metrics, period-over-period comparisons, or quantitative data are explicitly stated in the provided filing information. Sector is not specified, and no positive or negative performance indicators are mentioned.
30-01-2026
Amgen Inc filed an 8-K on January 30, 2026, disclosing under Item 1.02 the termination of a material definitive agreement. Item 9.01 provides financial statements and exhibits. No specific details on the agreement, parties, financial impacts, or quantitative metrics are disclosed.
30-01-2026
ProMIS Neurosciences Inc. filed a Form 8-K on January 30, 2026, reporting under Item 1.01 entry into a material definitive agreement, under Item 3.02 unregistered sales of equity securities, under Item 8.01 other events, and under Item 9.01 financial statements and exhibits. While the material agreement may represent a strategic development, the unregistered equity sales could imply potential shareholder dilution. No specific transaction details, financial impacts, or quantitative metrics are disclosed.
30-01-2026
Cibus, Inc. filed a Form 8-K on January 30, 2026 (AccNo: 0001193125-26-030591, Size: 496 KB), reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. This is a multi-item voluntary disclosure as Item 8.01 covers material events not specified in other items, with exhibits attached but details NOT_DISCLOSED. No financial metrics, transactions, or performance data are explicitly stated.
30-01-2026
TOMPKINS FINANCIAL CORP filed an 8-K on January 30, 2026 (AccNo: 0001005817-26-000020), reporting Results of Operations and Financial Condition under Item 2.02, Other Events under Item 8.01, and Financial Statements and Exhibits under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance revisions, period-over-period comparisons, or quantitative metrics were explicitly stated in the provided filing details. This multi-item filing pertains to financial results but lacks disclosed numerical data for performance assessment.
30-01-2026
FIRST FINANCIAL CORP /IN/ filed an 8-K on January 30, 2026, under Item 7.01 for Regulation FD Disclosure and Item 9.01 for Financial Statements and Exhibits. No specific financial metrics, transactions, events, or quantitative data are disclosed in the provided filing information. This appears to be a voluntary disclosure with attached exhibits, but details are NOT_DISCLOSED.
30-01-2026
PROCACCIANTI HOTEL REIT, INC. filed a Form 8-K on January 30, 2026 (AccNo: 0001104659-26-008505), reporting an Other Event under Item 8.01. No specific details regarding the nature of the event, financial metrics, transactions, or impacts are disclosed in the filing summary. This appears to be a single-item voluntary disclosure with no quantitative data provided.
30-01-2026
Cincinnati Financial Corp filed an 8-K on 2026-01-30 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers), along with Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the officer involved, position affected, reason for change, or timing are provided. No quantitative financial metrics, performance comparisons, or other numerical data are mentioned.
30-01-2026
PEOPLES FINANCIAL SERVICES CORP. filed an 8-K on January 30, 2026, disclosing an officer change or related event under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers). The filing also includes Regulation FD Disclosure under Item 7.01 and Financial Statements and Exhibits under Item 9.01. No specific details on the officer involved, position affected, reason for change, or any quantitative metrics are disclosed.
30-01-2026
Kelly Services Inc filed a multi-item Form 8-K on January 30, 2026 (AccNo: 0001193125-26-031768), reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation or Off-Balance Sheet Arrangement), Item 3.03 (Material Modifications to Rights of Security Holders), Item 5.01 (Changes in Control of Registrant), Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements), Item 7.01 (Regulation FD Disclosure), and Item 9.01 (Financial Statements and Exhibits). No specific transaction details, dollar values, named parties, quantitative metrics, or period-over-period comparisons are disclosed in the provided filing information.
30-01-2026
PEOPLES FINANCIAL SERVICES CORP. filed an 8-K on January 30, 2026, reporting results of operations and financial condition under Item 2.02. Item 9.01 includes financial statements and exhibits. No specific revenue, earnings, balance sheet metrics, period-over-period changes, or guidance were disclosed in the provided filing details.
30-01-2026
TuHURA Biosciences, Inc./NV filed a Form 8-K on January 30, 2026 (AccNo: 0001193125-26-031742), under Item 3.01, providing notice of delisting or failure to satisfy a continued listing rule or standard, or transfer of listing. No quantitative financial metrics, positive developments, or additional details such as reasons, impacts, or timelines were disclosed. This represents a material negative event with no offsetting positives mentioned.
- ·Filing size: 167 KB
- ·Sector: not specified
30-01-2026
Becton Dickinson & Co filed a Form 8-K on January 30, 2026, disclosing matters under Item 5.02 related to departure of directors or certain officers, election or appointment of directors or officers, and compensatory arrangements of certain officers. The filing also covers Item 5.07 on submission of matters to a vote of security holders and Item 9.01 on financial statements and exhibits. No specific details on positions affected, individuals involved, reasons for changes, voting outcomes, or exhibits are disclosed in the provided information.
30-01-2026
SB Financial Group, Inc. filed an 8-K on January 30, 2026, reporting results of operations and financial condition under Item 2.02, accompanied by financial statements and exhibits under Item 9.01. No specific revenue, earnings, balance sheet changes, guidance, or other quantitative financial metrics are disclosed in the provided filing information. This is an informational earnings-related disclosure with no directional data available for analysis.
30-01-2026
Esquire Financial Holdings, Inc. filed an 8-K on 2026-01-30 disclosing an officer change under Item 5.02 (Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers). Item 9.01 indicates financial statements and exhibits were included. No specific details on positions affected, names, reasons for change, timing, or financial metrics are disclosed.
30-01-2026
Velocity Financial, Inc. filed an 8-K on January 30, 2026, disclosing under Item 1.01 entry into a material definitive agreement and under Item 8.01 other events, with Item 9.01 listing financial statements and exhibits. No specific details on the agreement, events, dollar values, financial impacts, or performance metrics are disclosed in the provided filing summary. No positive or negative metrics, period-over-period comparisons, or quantitative data are mentioned.
30-01-2026
RCI Hospitality Holdings, Inc. filed a Form 8-K on January 30, 2026, reporting under Item 8.01 Other Events and Item 9.01 Financial Statements and Exhibits. No specific details regarding the nature of the other events or the content of the financial statements and exhibits are disclosed in the provided filing information. No quantitative financial metrics, positive or negative changes, or performance comparisons are mentioned.
30-01-2026
ARTELO BIOSCIENCES, INC. filed an 8-K on January 30, 2026, reporting under Item 5.07: Submission of Matters to a Vote of Security Holders, indicating results from a shareholder meeting were disclosed. No specific matters voted on, vote outcomes, numerical results, or other metrics are mentioned in the provided filing details. This is a single-item mandatory filing with no financial or operational impacts explicitly stated.
30-01-2026
USCB Financial Holdings, Inc. filed an 8-K on 2026-01-30 disclosing an officer change under Item 5.02, which covers departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers. Item 9.01 references financial statements and exhibits. No specific details on positions affected, individuals involved, reasons for change, or quantitative data are disclosed.
30-01-2026
30-01-2026
SMARTFINANCIAL INC. filed a Form 8-K on January 30, 2026, under Item 7.01 (Regulation FD Disclosure) and Item 9.01 (Financial Statements and Exhibits). This is a multi-item voluntary disclosure to comply with Regulation FD by publicly releasing material nonpublic information, with exhibits attached. No specific financial metrics, transactions, or performance details (positive, negative, or flat) are disclosed in the provided filing information.
Get daily alerts with 12 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 28 filings
🇺🇸 More from United States
View all →March 25, 2026
US Pre-Market SEC Filings Roundup — March 25, 2026
US Pre-Market SEC Filings Roundup
March 24, 2026
US Merger & Acquisition SEC Filings — March 24, 2026
US Merger & Acquisition SEC Filings
March 24, 2026
US Corporate Board Director Changes SEC Filings — March 24, 2026
US Corporate Board Director Changes SEC Filings
March 24, 2026
US Executive Officer Management Changes SEC — March 24, 2026
US Executive Officer Management Changes SEC